| Literature DB >> 27013783 |
Yoko Tsuzuki1, Yoriko Yamashita2, Yuka Hattori3, Guang Hua Li4, Shinya Akatsuka4, Tomomi Kotani5, Fumitaka Kikkawa5, Aya Naiki-Ito6, Satoru Takahashi6, Kimitoshi Nishiwaki7, Shinya Toyokuni4.
Abstract
Anesthesia is sometimes used for the reduction of maternal pain in normal human term labor, but whether the drugs affect oxidative stress remains unclear. The placenta serves as an interface between the maternal and fetal vasculature. In this study, we immunohistochemically analyzed two markers for oxidative stress, namely 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal-modified proteins (HNE), using placentas from 21 cases of normal tansvaginal delivery (V group), 20 Caesarean sections (C group), and 17 normal transvaginal deliveries with epidural anesthesia (E group). 8-OHdG staining in the nuclei of trophoblasts lining the chorionic villi was significantly stronger in the V group either compared with the C or E group (p<0.001), without significant differences in the C and E groups (p = 0.792). Moderate to intense staining by HNE of the intravascular serum of chorionic villi vasculature was frequently observed in the placentas from the V group, but less frequently of those in either C or E groups (p<0.001), nor the p value comparing the C and E groups was significant (p = 0.128) for HNE staining. Our results suggest that although the role of oxidative stress and its influences on fetal state in the placenta in labor remains unclear, it seems to be lessened by epidural anesthesia.Entities:
Keywords: 4-hydroxy-2-nonenal-modified proteins; 8-hydroxy-2'-deoxyguanosine; anesthesia; oxidative stress; placenta
Year: 2016 PMID: 27013783 PMCID: PMC4788402 DOI: 10.3164/jcbn.15-138
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.114
Clinical data of the 58 placentas
| Sample no. | Maternal age | Birth weight (g) | Gender of baby | Apgar score | Duration of labor (h:min) | Anesthetics | Complication | Multipara or primi-gravida |
|---|---|---|---|---|---|---|---|---|
| V-1 | 37 | 3,234 | male | 9 | 9:37 | — | n.p. | p |
| V-2 | 31 | 3,404 | male | 8 | 22:27 | — | n.p. | p |
| V-3 | 33 | 2,486 | female | 9 | 3:40 | — | n.p. | p |
| V-4 | 35 | 2,648 | female | 9 | 7:43 | — | n.p. | p |
| V-5 | 29 | 3,296 | male | 9 | 4:58 | — | n.p. | p |
| V-6 | 31 | 3,248 | male | 8 | 12:46 | — | n.p. | p |
| V-7 | 22 | 2,980 | female | 6:01 | — | n.p. | p | |
| V-8 | 26 | 2,790 | female | 9 | 11:39 | — | n.p. | p |
| V-9 | — | — | — | — | — | — | stillborn (34 weeks) | p |
| V-10 | 27 | 3,128 | male | 9 | 15:33 | — | n.p. | p |
| V-11 | 35 | 3,040 | female | 9 | 14:09 | — | n.p. | p |
| V-12 | 24 | 3,048 | female | 9 | 5:12 | — | n.p. | p |
| V-13 | 24 | 3,082 | male | 9 | 21:43 | — | n.p. | p |
| V-14 | 33 | 3,034 | female | 9 | 4:20 | — | n.p. | p |
| V-15 | 28 | 2,682 | male | 9 | 15:10 | — | n.p. | p |
| V-16 | 35 | 2,880 | male | 9 | 10:12 | — | n.p. | p |
| V-17 | 30 | 3,284 | female | 9 | 17:45 | — | n.p. | p |
| V-18 | 35 | 3,484 | female | 9 | 3:17 | — | n.p. | p |
| V-19 | 24 | 3,246 | female | 9 | 15:50 | — | n.p. | p |
| V-20 | 29 | 3,130 | male | 10 | 27:30 | — | n.p. | p |
| V-21 | 31 | 3,480 | female | 9 | 7:15 | — | n.p. | p |
| C-1 | 30 | 2,942 | male | 9 | — | 0.5% bupivacaine 2.6 ml | n.p. | NK |
| C-2 | 31 | 3,268 | male | 9 | — | propofol 100 mg, fentanyl 80 mg, pentazocine 30 mg, 1% sevoflurane 7 min, N2O 40l 32 min | n.p. | NK |
| C-3 | 30 | 2,960 | male | 9 | — | 0.5% bupivacaine 2.3 ml | n.p. | p |
| C-4 | 34 | 3,578 | male | 9 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-5 | 29 | 3,326 | male | 9 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-6 | 36 | 3,608 | male | 9 | — | 0.5% bupivacaine 2.6 ml | n.p. | p |
| C-7 | 25 | 2,536 | male | 9 | — | 0.5% bupivacaine 2.5 ml, fentanyl 0.4 ml | n.p. | p |
| C-8 | 29 | 2,980 | male | 9 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-9 | 32 | 3,488 | male | 8 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-10 | 33 | 3,098 | male | 10 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-11 | 36 | 3,310 | male | 8 | — | 0.5% bupivacaine 2.3 ml | n.p. | p |
| C-12 | 31 | 2,950 | male | 10 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-13 | 25 | 2,524 | male | 5 | — | 0.5% bupivacaine 2.5 ml × 2 | n.p. | p |
| C-14 | 33 | 3,284 | female | 9 | — | 0.5% bupivacaine 2.2 ml | n.p. | p |
| C-15 | 26 | 2,940 | male | 8 | — | 0.5% bupivacaine 2.3 ml | n.p. | p |
| C-16 | 31 | 2,818 | female | 8 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-17 | 26 | 2,940 | male | 8 | — | 0.5% bupivacaine 2.2 ml | n.p. | p |
| C-18 | 33 | 3,366 | male | 7 | — | 0.5% bupivacaine 2.2 ml | n.p. | p |
| C-19 | 28 | 2,986 | female | 9 | — | 0.5% bupivacaine 2.5 ml | n.p. | p |
| C-20 | 27 | 2,706 | female | 10 | — | 0.5% bupivacaine 2.2 ml | n.p. | p |
| E-1 | 34 | 3,210 | male | 9 | 6:32 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | mu |
| E-2 | 27 | 2,980 | male | 9 | 9:55 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-3 | 25 | 3,040 | male | 8 | 7:16 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-4 | 36 | 3,125 | male | 9 | 6:06 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-5 | 37 | 3,880 | male | 9 | 12:40 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | mu |
| E-6 | 28 | 2,770 | male | 9 | 4:20 | 0.25% levobupivacaine hydorochloride 10 ml | cervical cancer | p |
| E-7 | 33 | 3,230 | male | 9 | 3:08 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | mu |
| E-8 | 31 | 2,835 | male | 9 | 6:50 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-9 | 35 | 3,515 | male | 8 | 6:16 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-10 | 34 | 3,010 | female | 8 | 7:45 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-11 | 28 | 3,030 | female | 9 | 16:55 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-12 | 35 | 3,215 | male | 9 | 2:52 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | mu |
| E-13 | 32 | 3,545 | female | 9 | 13:20 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-14 | 35 | 3,265 | female | 9 | 7:07 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-15 | 29 | 3,105 | male | 9 | 16:10 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
| E-16 | 30 | 3,130 | female | 8 | 2:05 | 0.25% levobupivacaine hydorochloride 10 ml | hyperthyroidism | mu |
| E-17 | 28 | 3,050 | female | 8 | 6:16 | 0.25% levobupivacaine hydorochloride 10 ml | n.p. | p |
V group, normal transvaginal delivery; C group, Caeserean section group; E group, normal transvaginal delivery with anesthesia. n.p., nothing particular; p, primigravida; mu, multipara; NK, not known.
Fig. 1Immunostaining results of 20 chorionic villi stained with 8-hydroxy-2'-deoxyguanosine (8-OHdG) are shown for the V group (A), C group (B), and E group (C). Signal intensities greater than 70 are highlighted in red; this was done by the BZ9000 analysis software. Many red signals are observed in the V group compared to in the C group and E group. The results of immunostaining for 4-hydroxy-2-nonenal-modified protein (HNE) are shown for the V group (D), C group (E) and E group (F). Note that some cross sections of the vessels are positive in the chorionic villi of the V group (arrows). Hematoxylin and eosin (H&E) staining of representative sections of placentas from the V group (normal transvaginal delivery) (G), C group (Caesarean section) (H), and E group (transvaginal delivery with epidural anesthesia) (I).
Fig. 2(A) Signal intensity of immunopositivity for 8-hydroxy-2'-deoxyguanosine (8-OHdG) for the V (normal transvaginal delivery), C (Caesarean section), and E (transvaginal delivery with epidural anesthesia) groups. (B) Number of positive vessels per low-magnification area identified by 4-hydroxy-2-nonenal–modified proteins (HNE) immunostaining for the 3 groups. ***p<0.001.
Fig. 3Labor duration and oxidative stress. Labor time (h: hours) and signal intensity of immunopositivity for 8-hydroxy-2'-deoxyguanosine (8-OHdG) for the V (normal transvaginal delivery) group (A) and E (transvaginal delivery with epidural anesthesia) group (B); number of positive vessels identified by 4-hydroxy-2-nonenal–modified protein (HNE) immunostaining for the V group (C), and E group (D).